BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS


Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


 Key Statistics


Email:
Ownership:

Web Site: Biogen Idec, Inc. (Massachusetts)
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display





 Company News
Swedish Orphan Biovitrum Expands Haemophilia Development Portfolio - Elects To Include Potentially Longer-Acting Haemophilia A Candidate In Collaboration Agreement With Biogen Idec, Inc. (Massachusetts) (BIIB) 9/19/2014 10:06:29 AM
Detailed Results From Biogen Idec, Inc. (Massachusetts) (BIIB) And AbbVie (ABBV)’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process) 9/12/2014 10:51:06 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Suddenly Struggling To Keep Up With The Biotech Joneses 9/12/2014 6:52:03 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients 9/11/2014 10:57:48 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance Of Efficacy And Safety In Multiple Sclerosis Patients 9/11/2014 10:55:25 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New International Survey Finds MS Patients And Neurologists View Communication Positively, Yet Struggle To Discuss Key MS Symptoms 9/10/2014 11:35:11 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) To Present At Morgan Stanley (MST) Global Healthcare Conference 2014 9/3/2014 1:54:00 PM
Biogen Idec, Inc. (Massachusetts) (BIIB) Data At Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio And Commitment To Advancing Patient Care 9/3/2014 9:04:27 AM
Novartis AG (NVS) Follows Biogen Idec, Inc. (Massachusetts) (BIIB), GlaxoSmithKline (GSK)'s Footsteps With New State Of The Art Offices; Space Reflects "The Novartis Way Of Working" 8/29/2014 6:05:51 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) In Panel At The Citi 9th Annual Biotech Conference 8/27/2014 9:03:27 AM
12345678910...